IQVIA

IQVIA provides data analytics, technology solutions, and clinical research services to the life sciences industry, including pharmaceutical, biotech, and medical device companies. The company operates globally, offering commercial analytics, healthcare intelligence, and R&D solutions to improve patient outcomes and operational efficiency.

In Q1 2026, IQVIA reported $4.15 billion revenue, an 8.4% year-over-year increase. Commercial Solutions grew 11.6% to $1.75 billion, while R&D Solutions reached $2.40 billion, up 6.2%. The company reaffirmed its full-year guidance, raising Adjusted EPS forecast to $12.65-$12.95.

IQVIA's AI-enabled solutions focus on patient analytics and commercial applications. These tools help pharmaceutical companies optimize drug development, track prescription trends, and improve healthcare outcomes. Recent data analysis included tracking Lilly's obesity pill prescriptions during its launch week.

IQVIA serves pharmaceutical companies, biotechnology firms, medical device manufacturers, healthcare providers, and government agencies. Its solutions support clinical research, commercial analytics, and regulatory compliance across the life sciences sector, with operations in over 100 countries.

IQVIA's strengths include a $34.2 billion R&D Solutions backlog, global presence in 100+ countries, and growth in AI-driven commercial analytics. The company's diversified portfolio and evidence-based solutions position it as a leader in life sciences intelligence and technology.

IQVIA's challenges include high net debt of $13.89 billion, dependence on converting its R&D backlog, and market volatility affecting pharmaceutical R&D spending. The company must maintain innovation and execution to sustain growth amid evolving healthcare industry dynamics.